论文部分内容阅读
目的观察尿激酶胸膜腔注射治疗青少年结核性胸膜炎疗效及毒副反应。方法对确诊结核性胸膜炎,年龄在13-25岁,X-线检查提示胸腔积液量为中到大量的48例患者,随机分为治疗组和对照组各24例,在常规抗结核治疗联合局部胸膜腔穿刺抽取胸水治疗基础上,治疗组于每次胸穿后给予尿激酶10万u胸膜腔注射。结果强化期2个月结束,治疗组病例较对照组出现胸膜粘连、肥厚几率明显减少,胸水吸收时间缩短(P<0.01),治疗组没有出现因为应用尿激酶而引发的毒副反应。结论尿激酶胸膜腔注射治疗青少年结核性胸膜炎,可促进胸液吸收,减少胸膜粘连、肥厚,改善肺功能,增进了疗效。
Objective To observe the efficacy and side effects of pleural cavity injection of urokinase in treating juvenile tuberculous pleurisy. Methods Forty-eight patients diagnosed with tuberculous pleurisy, aged from 13 to 25 years old, with X-ray examination of medium to large volume of pleural effusion were randomly divided into treatment group and control group, 24 cases in each group. After conventional anti-tuberculosis therapy combined Local pleural puncture extraction of hydrothorax on the basis of treatment, the treatment group was given after each thoracentesis urokinase 100,000 u pleural cavity injection. Results The end of intensive phase 2 months, the treatment group than in the control group pleural adhesions, significantly reduced the risk of hypertrophy, pleural effusion shortened (P <0.01), the treatment group did not appear due to the application of urokinase caused by toxic and side effects. Conclusions Urokinase intrapleural injection of juvenile tuberculous pleurisy can promote pleural fluid absorption, reduce pleural adhesions, hypertrophy, improve lung function and improve the curative effect.